Cellectar Biosciences, Inc. financial data

Symbol
CLRB on Nasdaq
Industry
Pharmaceutical Preparations
Location
100 Campus Drive, Florham Park, New Jersey
State of incorporation
Delaware
Fiscal year end
December 31
Former names
NOVELOS THERAPEUTICS, INC. (to 2/11/2014), COMMON HORIZONS INC (to 6/2/2005)
Latest financial report
10-Q - Q1 2024 - May 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 149 % -53.3%
Debt-to-equity 493 % +963%
Return On Equity -1.86K % -734%
Return On Assets -246 % -61.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 32.3M shares +231%
Common Stock, Shares, Outstanding 33.2M shares +240%
Entity Public Float 18.9M USD -22.2%
Common Stock, Value, Issued 332 USD +242%
Weighted Average Number of Shares Outstanding, Basic 29.3M shares +161%
Weighted Average Number of Shares Outstanding, Diluted 29.3M shares +161%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 28.9M USD +31.6%
General and Administrative Expense 13.3M USD +41.8%
Costs and Expenses 42.3M USD +34.7%
Operating Income (Loss) -42.3M USD -34.7%
Nonoperating Income (Expense) -8.79M USD -3282%
Net Income (Loss) Attributable to Parent -51M USD -64.2%
Earnings Per Share, Basic -3.09 USD/shares +18.9%
Earnings Per Share, Diluted -3.09 USD/shares +18.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 40M USD +216%
Assets, Current 41.4M USD +199%
Property, Plant and Equipment, Net 1.02M USD +172%
Operating Lease, Right-of-Use Asset 487K USD -10.9%
Other Assets, Noncurrent 6.21K USD 0%
Assets 42.9M USD +189%
Accounts Payable, Current 5.62M USD +120%
Liabilities, Current 16.3M USD +134%
Operating Lease, Liability, Noncurrent 474K USD -13.5%
Liabilities 16.7M USD +123%
Retained Earnings (Accumulated Deficit) -239M USD
Stockholders' Equity Attributable to Parent 26.2M USD +257%
Liabilities and Equity 42.9M USD +189%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -13.4M USD -86%
Net Cash Provided by (Used in) Financing Activities 43.8M USD +1461648800%
Net Cash Provided by (Used in) Investing Activities -21.6K USD
Common Stock, Shares Authorized 170M shares +6.25%
Common Stock, Shares, Issued 33.2M shares +240%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 30.5M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 40M USD +216%
Deferred Tax Assets, Valuation Allowance 87.9M USD +20.6%
Deferred Tax Assets, Gross 88.1M USD +20.5%
Operating Lease, Liability 548K USD -8.67%
Payments to Acquire Property, Plant, and Equipment 21.6K USD
Lessee, Operating Lease, Liability, to be Paid 765K USD -14.5%
Property, Plant and Equipment, Gross 1.98M USD +77.8%
Operating Lease, Liability, Current 74K USD +44.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 146K USD +10.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 108K USD +1.89%
Operating Lease, Weighted Average Discount Rate, Percent 0.14 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 217K USD -26.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 150K USD +2.04%
Preferred Stock, Shares Issued 111 shares 0%
Preferred Stock, Shares Authorized 7K shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 153K USD +2%
Additional Paid in Capital 248M USD +27.9%
Preferred Stock, Shares Outstanding 111 shares 0%
Depreciation, Depletion and Amortization 88.5K USD +108%
Deferred Tax Assets, Net of Valuation Allowance 87.9M USD +20.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%